Time period 1995–1998 | Time period 1999–2002 | |||||
Diabetes | Diabetes | |||||
No(n = 22 582) | Yes(n = 5679) | OR for diabetes(95% CI) | No(n = 33427) | Yes(n = 9134) | OR for diabetes(95% CI) | |
Baseline characteristics | ||||||
Age (years, mean)* | 66.4 | 68.1 | 1.19 (1.15–1.23) | 66.5 | 68.4 | 1.21 (1.19–1.24) |
Male (%) | 70.8 | 63.4 | 0.72 (0.67–0.76) | 69.0 | 63.2 | 0.77 (0.73–0.81) |
Previous diseases | ||||||
Hypertension | 29.2 | 45.4 | 2.02 (1.90–2.14) | 30.7 | 50.1 | 2.26 (2.16–2.37) |
Smoker | 27.6 | 17.3 | 0.55 (0.51–0.59) | 29.5 | 19.3 | 0.57 (0.54–0.61) |
MI | 21.2 | 33.0 | 1.83 (1.71–1.95) | 16.7 | 27.8 | 1.93 (1.82–2.03) |
Heart failure | 7.0 | 16.8 | 2.68 (2.46–2.92) | 6.6 | 17.2 | 2.92 (2.73–3.13) |
PCI | 3.1 | 4.4 | 1.43 (1.23–1.66) | 3.7 | 6.0 | 1.66 (1.49–1.84) |
CABG | 4.3 | 6.0 | 1.45 (1.27–1.64) | 5.3 | 7.7 | 1.73 (1.58–1.88) |
PCI/CABG | 6.8 | 9.5 | 1.45 (1.31–1.61) | 8.1 | 13.1 | 1.72 (1.60–1.85) |
Treatment on admission | ||||||
Aspirin | 29.7 | 42.7 | 1.76 (1.66––1.87) | 30.2 | 46.8 | 2.04 (1.94–2.13) |
Beta-blocker | 29.3 | 38.6 | 1.51 (1.42–1.61) | 29.7 | 44.0 | 1.86 (1.77–1.95) |
ACE inhibitor | 10.7 | 26.9 | 3.06 (2.84–3.29) | 12.9 | 32.8 | 3.29 (3.12–3.48) |
Calcium antagonist | 15.6 | 23.7 | 1.68 (1.56–1.81) | 13.9 | 22.1 | 1.76 (1.66–1.86) |
Lipid-lowering drugs | 6.7 | 10.6 | 1.64 (1.48–1.81) | 12.1 | 24.9 | 2.42 (2.28–2.56) |
Diuretics | 19.9 | 38.8 | 2.55 (2.39–2.72) | 17.9 | 37.5 | 2.75 (2.61–2.89) |
Oral anticoagulant | 5.8 | 8.1 | 1.45 (1.30–1.62) | 5.6 | 9.2 | 1.71 (1.57–1.86) |
Nitroglycerin | 16.5 | 27.5 | 1.91 (1.79–2.05) | 12.7 | 22.8 | 2.03 (1.92–2.15) |
Treatment in hospital | ||||||
Anticoagulants (subcutaneous, intravenous) | 57.7 | 62.7 | 1.23 (1.16–1.31) | 37.5 | 42.6 | 1.24 (1.18–1.30) |
Beta-blocker (intravenous) | 31.9 | 28.1 | 0.83 (0.78–0.89) | 40.4 | 35.7 | 0.82 (0.78–0.86) |
Reperfusion† | 41.1 | 31.0 | 0.64 (0.61–0.69) | 36.8 | 26.1 | 0.60 (0.57–0.64) |
Revascularisation‡ | 5.1 | 3.9 | 0.75 (0.65–0.88) | 8.2 | 5.4 | 0.64 (0.58–0.71) |
Complications at hospital | ||||||
Atrial fibrillation | 13.9 | 18.5 | 1.42 (1.32–1.54) | 12.5 | 17.5 | 1.50 (1.41–1.60) |
Heart failure | 37.6 | 50.7 | 1.71 (1.61–1.81) | 30.1 | 45.4 | 1.93 (1.84–2.03) |
Treatment at discharge | ||||||
Aspirin | 84.2 | 80.1 | 0.76 (0.70–0.82) | 87.7 | 84.1 | 0.74 (0.69–0.79) |
Beta blocker | 79.7 | 74.6 | 0.75 (0.70–0.81) | 84.5 | 82.4 | 0.85 (0.80–0.91) |
ACE inhibitor | 34.4 | 49.7 | 1.88 (1.77–2.00) | 40.5 | 57.6 | 1.99 (1.90–2.09) |
Calcium antagonist | 13.3 | 19.3 | 1.56 (1.44–1.69) | 11.8 | 17.7 | 1.61 (1.51–1.72) |
Lipid-lowering drugs | 27.5 | 25.1 | 0.89 (0.82–0.95) | 58.9 | 54.8 | 0.85 (0.81–0.89) |
Diuretics | 32.8 | 53.6 | 2.37 (2.23–2.53) | 29.2 | 51.6 | 2.59 (2.47–2.72) |
Digitalis | 7.7 | 14.2 | 1.99 (1.81–2.18) | 5.3 | 10.8 | 2.16 (1.99–2.35) |
Nitroglycerin | 36.3 | 45.2 | 1.45 (1.36–1.54) | 28.6 | 37.3 | 1.48(1.41–1.56) |
Oral anticoagulant | 20.0 | 20.7 | 1.04 (0.97–1.13) | 22.4 | 23.8 | 1.08 (1.02–1.14) |
Heparin | 6.5 | 6.0 | 0.91 (0.80–1.04) | 13.8 | 13.2 | 0.96 (0.89–1.02) |
Glucose lowering therapy (oral) | 39.1 | 37.9 | ||||
Insulin | 30.6 | 30.4 | ||||
Combination | 7.7 | 11.6 | ||||
Revascularisation <14 days | 13.4 | 10.2 | 0.74 (0.67–0.81) | 27.5 | 20.5 | 0.68 (0.64–0.72) |
Values are percentages if not otherwise stated.
*OR for age represents the increase in relative odds of being a diabetic patient for an increase of 1 SD of age (10.2 years) in the whole sample.
†Reperfusion; acute thrombolysis or acute PCI.
‡Revascularisation; acute PCI or CABG or both.